Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer

Evasion from apoptosis is a hallmark of cancer. Inhibitor of apoptosis proteins (IAPs) contribute to this hallmark by suppressing the induction of cell death. IAPs were found to be overexpressed in cancerous tissues and to contribute to therapeutic resistance. The present review focuses on the IAP m...

Descripción completa

Detalles Bibliográficos
Autor principal: Wolf, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950391/
https://www.ncbi.nlm.nih.gov/pubmed/36845731
http://dx.doi.org/10.3389/fonc.2023.1124600
_version_ 1784893152807616512
author Wolf, Philipp
author_facet Wolf, Philipp
author_sort Wolf, Philipp
collection PubMed
description Evasion from apoptosis is a hallmark of cancer. Inhibitor of apoptosis proteins (IAPs) contribute to this hallmark by suppressing the induction of cell death. IAPs were found to be overexpressed in cancerous tissues and to contribute to therapeutic resistance. The present review focuses on the IAP members cIAP1, cIAP2, XIAP, Survivin and Livin and their importance as potential therapeutic targets in bladder cancer.
format Online
Article
Text
id pubmed-9950391
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99503912023-02-25 Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer Wolf, Philipp Front Oncol Oncology Evasion from apoptosis is a hallmark of cancer. Inhibitor of apoptosis proteins (IAPs) contribute to this hallmark by suppressing the induction of cell death. IAPs were found to be overexpressed in cancerous tissues and to contribute to therapeutic resistance. The present review focuses on the IAP members cIAP1, cIAP2, XIAP, Survivin and Livin and their importance as potential therapeutic targets in bladder cancer. Frontiers Media S.A. 2023-02-10 /pmc/articles/PMC9950391/ /pubmed/36845731 http://dx.doi.org/10.3389/fonc.2023.1124600 Text en Copyright © 2023 Wolf https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wolf, Philipp
Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
title Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
title_full Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
title_fullStr Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
title_full_unstemmed Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
title_short Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
title_sort inhibitor of apoptosis proteins as therapeutic targets in bladder cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950391/
https://www.ncbi.nlm.nih.gov/pubmed/36845731
http://dx.doi.org/10.3389/fonc.2023.1124600
work_keys_str_mv AT wolfphilipp inhibitorofapoptosisproteinsastherapeutictargetsinbladdercancer

Ejemplares similares